Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna L Godfrey

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Cancer Cell|November 16, 2010
Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signalingEdwin Chen, Philip A Beer, Anna L Godfrey, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 8, 2014
JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint responseEdwin Chen, Jong Sook Ahn, Charlie E Massie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2018
Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk FeaturesAnna L Godfrey, Peter J Campbell, Cathy MacLean, et al.
British Journal of Haematology|July 14, 2024
Clinical utility of investigations in triple-negative thrombocytosis: A real-world, multicentre evaluation of UK practiceAnna L Godfrey, Nikolaos Sousos, Rebecca Frewin, et al.
Nature Genetics|January 17, 2024
Inherited polygenic effects on common hematological traits influence clonal selection on JAK2<sup>V617F</sup> and the development of myeloproliferative neoplasmsJing Guo, Klaudia Walter, Pedro M Quiros, et al.
Leukemia|December 5, 2022
Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patientsHosuk Ryou, Korsuk Sirinukunwattana, Alan Aberdeen, et al.
Blood|April 3, 2014
JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain diseaseJuan Li, David G Kent, Anna L Godfrey, et al.
Cancer Discovery|April 20, 2026
Genomic evolution and natural history of myeloproliferative neoplasms on therapyDaniel Leongamornlert, Joe Lee, Aleksandra E Kamizela, et al.
Blood|August 18, 2012
JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subcloneAnna L Godfrey, Edwin Chen, Francesca Pagano, et al.
British Journal of Haematology|October 13, 2012
Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutationsAnthony J Bench, Helen E White, Letizia Foroni, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Cancer Cell|November 16, 2010
Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signalingEdwin Chen, Philip A Beer, Anna L Godfrey, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 8, 2014
JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint responseEdwin Chen, Jong Sook Ahn, Charlie E Massie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2018
Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk FeaturesAnna L Godfrey, Peter J Campbell, Cathy MacLean, et al.
British Journal of Haematology|July 14, 2024
Clinical utility of investigations in triple-negative thrombocytosis: A real-world, multicentre evaluation of UK practiceAnna L Godfrey, Nikolaos Sousos, Rebecca Frewin, et al.
Nature Genetics|January 17, 2024
Inherited polygenic effects on common hematological traits influence clonal selection on JAK2<sup>V617F</sup> and the development of myeloproliferative neoplasmsJing Guo, Klaudia Walter, Pedro M Quiros, et al.
Leukemia|December 5, 2022
Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patientsHosuk Ryou, Korsuk Sirinukunwattana, Alan Aberdeen, et al.
Blood|April 3, 2014
JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain diseaseJuan Li, David G Kent, Anna L Godfrey, et al.
Cancer Discovery|April 20, 2026
Genomic evolution and natural history of myeloproliferative neoplasms on therapyDaniel Leongamornlert, Joe Lee, Aleksandra E Kamizela, et al.
Blood|August 18, 2012
JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subcloneAnna L Godfrey, Edwin Chen, Francesca Pagano, et al.
British Journal of Haematology|October 13, 2012
Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutationsAnthony J Bench, Helen E White, Letizia Foroni, et al.
Pageof 3